Atlas Trials

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Clinical trial NCT02396511 · COMPLETED

Trial details

NCT number
NCT02396511
Sponsor
Tracon Pharmaceuticals Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Choriocarcinoma
Start date
2015-01-01
Primary completion
2017-12-01
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.